Understanding the Epidemic of Fatty Liver Disease

Thursday, May 12, 2022

1:30 PM – 1:50 PM

Location: Main Stage - Sapphire IJMN (Level 4)

Speaker(s)

Scott D. Isaacs, MD, FACP, FACE
Adjunct Assistant Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia, United States

Disclosure: Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Medpace (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Quest (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21)

PDF Slides

Learning Objectives:

Discuss the prevalence of NAFLD/NASH in the United States and worldwide.
Describe noninvasive tests used for identification of patients with NAFLD, NASH and identify those who are at high risk for clinically significant liver fibrosis.
Review the efficacy of various treatments for NAFLD/NASH.

Participants should be aware of the following financial/non-financial relationships:

Scott D. Isaacs, MD, FACP, FACE: Madrigal (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Medpace (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Quest (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)